NEATstik®, a rapid test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017. This achievement follows on from the launch of the ProteaseTag® Active Neutrophil Elastase Immunoassay in 2016. A range of other laboratory-based immunoassays and point-of-care tests designed for routine monitoring of chronic diseases are in development.
ProAxsis also offers a highly experienced team who can provide clinical trial support services in regard to the specific measurement of active proteases and other inflammatory biomarkers within clinical samples.
ProAxsis was founded in August 2013 by Professor Brian Walker and Dr Lorraine Martin, School of Pharmacy, Queen’s University Belfast. By September, ProAxsis had won the overall Northern Ireland Science Park’s 25K Award for entrepreneurialism and in February 2014, the first seed investment from partners NetScientific plc and QUBIS Ltd was secured. In September 2014, they were the first company in Northern Ireland to win a prestigious Horizon 2020 SME Instrument Award.
Dr David Ribeiro has extensive experience in commercialising products within chronic diseases, having previously held senior management roles at Solvay Healthcare, Encysive Pharmaceuticals and …
Dr Kelly Moffitt has extensive research experience in the role of host proteases involved in both inflammation and infection, particularly within various respiratory diseases …
Darragh McCafferty graduated in 2004 with a Master of Pharmacy degree from Queen’s University Belfast, and completed his pre-registration training in community pharmacy. In …
Timothy graduated from Queen’s University Belfast with a Master of Pharmacy degree in 2011. Following successful completion of pre-registration training, he returned to the …
Professor Brian Walker, a co-founder of ProAxsis Ltd., has over 30 years of experience in the design and synthesis of “Protease-Tags” for the identification …
Lorraine Martin is a Professor of Biomolecular Sciences, School of Pharmacy, Queen’s University Belfast (QUB) and a co-founder of ProAxsis Ltd. As an expert …
François Martelet, Chief Executive Officer, joined NetScientific Mid 2015. He brings over 20 years of biopharma experience and a proven track record of shaping …
Dr David Ribeiro has extensive experience in commercialising products within chronic diseases, having previously held senior management roles at Solvay Healthcare, Encysive Pharmaceuticals and …
Professor Brian Walker, a co-founder of ProAxsis Ltd., has over 30 years of experience in the design and synthesis of “Protease-Tags” for the identification …
Ian Postlethwaite, Chief Financial Officer, joined NetScientific in June 2016. He brings over 14 years of biopharma experience and a proven track record of …
Lorraine Martin is a Professor of Biomolecular Sciences, School of Pharmacy, Queen’s University Belfast (QUB) and a co-founder of ProAxsis Ltd. As an expert …
David is Investment Manager with QUBIS Ltd, the early stage investment fund responsible for the commercialisation of technology from The Queen’s University of Belfast. …
Professor Elborn is Clinical Professor of Respiratory Medicine and Centre Director for Adult Cystic Fibrosis at the Royal Brompton Hospital, London. He was formerly …
Professor Chalmers is a Wellcome Trust Postdoctoral Fellow, Senior Clinical Lecturer and Honorary Consultant Respiratory Physician at the University of Dundee. He is chair …
Professor Mona Bafadhel is an Associate Professor in Respiratory Medicine and NIHR Post Doctoral Fellow at the University of Oxford and holds an Honorary …
Patrick Flume is a Professor of Medicine and Pediatrics at the Medical University of South Carolina. He oversees a rapidly growing CF Center, including …
Dr Sagel is a pediatric pulmonologist who focuses on airway inflammation and lung disease in children with cystic fibrosis and primary ciliary dyskinesia. He …
Penny has worked at the Royal Brompton and Harefield NHS Foundation Trust since 1996 and is currently the Director of Rehabilitation and Therapies. Her …
Marcus Mall is professor of Paediatrics and director of the Department of Translational Pulmonology at the Heidelberg University Medical School, and head of the …
ProAxsis is a core subsidiary of NetScientific plc.
NetScientific identifies, develops and commercializes transformative biomedical and healthcare technologies originating from leading universities, teaching hospitals and research institutes, with a focus on United Kingdom and United States.
More information about NetScientific’s purpose, core strategy and investment model can be viewed on the
QUBIS, established in 1984, was one of the first University investment companies in the UK and Ireland and had a goal of commercialising the research and development activities of Queen’s University through the formation of spin-out businesses. Working with academic entrepreneurs, QUBIS Ltd has continued to grow a portfolio of shareholdings in viable companies that have succeeded on an international level. Queen’s remains one of the top universities in the UK for the level of revenue generated by spin-out companies, and has created over 60 companies to date.
ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland
tel +44 (0)28 9073 0444
email info@proaxsis.com
